Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRI-301
- Development stage
- Preclinical
- Lead developer
- BRI Pharma
- Modality
- Small Molecules
01
Overview
BRI-301 is a small-molecule therapeutic candidate being developed by BRI Pharma, a Japanese biotechnology company focused on neurodegenerative diseases. It acts through a novel multi-target mechanism as an activator of T-type calcium channels, calmodulin-dependent protein kinase (CaMK), and the proteasome. This triple-action approach is designed to provide disease-modifying effects by enhancing synaptic function and promoting the clearance of pathogenic protein aggregates. BRI-301 is currently the lead candidate in BRI Pharma's pipeline and is being investigated for the treatment of Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB), Parkinson's disease (PD), dystonia, and depression.
Beyond the preview
Go deeper on BRI-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRI-301.